侵袭性肺真菌病诊断与治疗临床实践指南(2025版)
中华医学会呼吸病学分会感染学组组织多学科专家,基于2007版共识及EORTC/MSGERC指南,结合国内外研究进展制定2025版指南。指南涵盖IPFD十一个方面,以综述与问题结合形式提出16条推荐意见,聚焦诊断与治疗关键问题。
要点
- 高危患者应预防性抗真菌治疗至少3周直至宿主因素改善。
- 持续中性粒细胞减少伴广谱抗菌治疗无效发热者应经验性抗真菌治疗。
- 肺隐球菌病伴神经系统症状、高滴度CrAg或免疫抑制者应行腰椎穿刺。
核心结论
- 2025版指南针对侵袭性肺真菌病提出16条推荐意见,覆盖预防、诊断、治疗及特殊情形处理。
研究设计与样本
- 由中华医学会呼吸病学分会感染学组组织多学科专家制定,基于2007版共识及EORTC/MSGERC指南,结合国内外研究进展与国内临床经验。
主要发现
- 指南涵盖流行病学、宿主因素、临床影像特征、诊断方法、分层诊断标准、治疗药物、治疗方案、免疫重建炎症综合征、疗效评估、常见诊疗问题及罕见肺真菌病共十一个方面。
关键数值与推荐
- 推荐1:异基因造血干细胞移植、肺移植、严重粒细胞缺乏及接受大剂量免疫抑制剂的高危患者,预防用药至少3周直至宿主因素改善(证据等级2)。
- 推荐2:持续中性粒细胞减少且广谱抗菌治疗仍反复发热者,启动经验性抗真菌治疗直至病情稳定及微生物学和/或影像学恢复正常(证据等级2)。
- 推荐3:临床疑似侵袭性肺曲霉病尤其气道侵袭性者,推荐支气管镜早期诊断(证据等级3)。
- 推荐8:肺隐球菌病伴神经系统症状、高血清CrAg滴度或免疫抑制状态者应行腰椎穿刺(证据等级3)。
- 推荐9:氟康唑耐药或治疗失败者,重症予L-AmB(3-6 mg·kg-1·d-1)联合5-FC(100 mg·kg-1·d-1)诱导4周后氟康唑(800 mg/d)或伏立康唑维持(证据等级2);轻中症或不耐受两性霉素B者予伏立康唑、泊沙康唑或艾沙康唑6-12个月(证据等级2)。
临床怎么用
- 对高危患者按推荐进行预防性抗真菌治疗并动态评估宿主因素。
- 疑似侵袭性肺曲霉病应尽早行支气管镜检查,必要时联合镜下介入治疗。
- 肺隐球菌病患者需根据神经系统症状、CrAg滴度及免疫状态决定是否腰穿。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To further standardize the diagnosis and treatment of invasive pulmonary fungal disease (IPFD) in China, particularly in non-immunosuppressed patients, and to enhance medical professionals' competence, the Infectious Diseases Group of Chinese Thoracic Society has organized experts to develop the Guidelines for the diagnosis and treatment of invasive pulmonary fungal disease (2025 Edition). These guidelines are based on the 2007 Chinese Expert Consensus on Pulmonary Mycosis and reference guidelines issued by the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORTC/MSGERC), integrating recent domestic and international research findings as well as clinical experience in China. The guideline development process incorporated feedback from multidisciplinary experts in pulmonology, infection, microbiology, laboratory testing, and neurology. The guidelines comprehensively cover eleven aspects of IPFD, including epidemiology, host factors, clinical and imaging features, diagnostic methods, hierarchical diagnostic criteria, therapeutic drugs, treatment regimens, immune reconstitution inflammatory syndrome, efficacy evaluation, common diagnostic and treatment issues, and rare pulmonary fungal diseases. Presented in a combined review-and-question format, the 2025 Edition provides sixteen evidence-based recommendations on key diagnostic and therapeutic issues, serving as a reference for Chinese medical practitioners.Recommendation 1: For allogeneic hematopoietic stem cell transplant recipients, lung transplant recipients, patients with severe granulocytopenia, and those at high risk of invasive pulmonary aspergillosis receiving high-dose immunosuppressive agents, prophylaxis should be given for at least 3 weeks until host factors have improved (evidence level: 2).Recommendation 2: For patients with persistent neutropenia and recurrent fever despite broad-spectrum antibacterial therapy, empirical antifungal therapy should be initiated and continued until the clinical condition stabilizes and the relevant microbiological and/or radiological findings have normalized (evidence level: 2).Recommendation 3: Bronchoscopy is recommended for the early diagnosis of clinically suspected invasive pulmonary aspergillosis, particularly in case of airway invasive aspergillosis (evidence level: 3).Recommendation 4: In addition to active antifungal therapy, bronchoscopic interventional procedures, including bronchoscopic injection and spraying of antifungal drugs, can be used for airway invasive aspergillosis. For massive hemoptysis, interventional treatments such as balloon occlusion under bronchoscopy and bronchial artery embolization can be considered (evidence level: 4).Recommendation 5: Inhalation of nebulized antifungal drugs is recommended for patients with invasive pulmonary aspergillosis combined with bronchial pulmonary aspergillosis when systemic antifungal treatment is not feasible, as well as for high-risk populations as prophylactic measure (evidence level: 3).Recommendation 6: For patients with severe, refractory, or treatment-failure invasive pulmonary aspergillosis, combination therapy with triazoles plus echinocandins and/or polyenes, or with echinocandins plus polyenes, is recommended. (evidence level: 4).Recommendation 7: A positive cryptococcal capsular polysaccharide antigen (CrAg) test indicates cryptococcal infection and is valuable for diagnostic purpose, but it should not be used to assess treatment efficacy or guide drug withdrawal (evidence level: 4).Recommendation 8: Lumbar puncture should be performed in patients with pulmonary cryptococcosis and neurological symptoms, high serum CrAg titres, or immunocompromised status (evidence level: 3).Recommendation 9: For patients with fluconazole resistance or treatment failure, the following: 1) Severe infection: induction therapy with L-AmB (3-6 mg·kg-1·d-1) and 5-FC (100 mg·kg-1·d-1) should continue for 4 weeks, followed by maintenance with fluconazole (800 mg/d) or voriconazole (evidence level: 2). 2) Mild to moderate infection or amphotericin B intolerance: voriconazole, posaconazole, or isaconazole should be used for 6-12 months (evidence level: 2). 3) If L-AmB is unavailable, consider 5-FC with fluconazole (800-1200 mg/d) (evidence level: 3).Recommendation 10: Combination antifungal therapy is not routinely recommended for pulmonary mucormycosis but can be used for severe infection or inadequate monotherapy response (evidence level: 4).Recommendation 11: Surgical treatment of pulmonary mucormycosis should include early evaluation, individualized decision-making, and multidisciplinary collaboration. Early surgical evaluation is crucial for localized lesions, whereas dynamic evaluation is needed for multiple lesions or high-risk patients (evidence level: 4).Recommendation 12: Patients with clinically diagnosed or confirmed pulmonary mucormycosis should be treated with local drug infusion via bronchoscopy (evidence level: 4).Recommendation 13: For patients with confirmed pulmonary mucormycosis who are scheduled for surgery or deemed inoperable, local debridement should be performed via bronchoscopy by an experienced team (evidence level: 4).Recommendation 14: Echinocandin treatment alone is not recommended for Pneumocystis pneumonia. Echinocandin combined with SMX-TMP is recommended for severe cases with respiratory failure. This combination is also recommended as second-line therapy when SMX-TMP use is limited by renal impairment (evidence level: 2).Recommendation 15: Consider echinocandin with other second-line agents if initial SMX-TMP treatment fails or in cases of patient intolerance or resistance (evidence level: 4).Recommendation 16: Use low-dose glucocorticoids early in severe pneumocystis pneumonia with hypoxemia but not in patients without hypoxemia (evidence level: 2). 为进一步规范我国侵袭性肺真菌病(IPFD),特别是非免疫抑制宿主IPFD(IPFDNIH)的诊治,提高广大医务工作者的诊治水平,中华医学会呼吸病学分会感染学组组织相关领域的专家,参考欧洲癌症研究与治疗组织和真菌研究小组教育与研究联合会(EORTC/MSGETC)等组织制订的相关指南和专家共识,结合国内外近年来的研究进展、我国的实际情况与诊治经验,广泛征求国内多学科专家的意见,对《肺真菌病诊断与治疗专家共识(2007年版)》进行了全面更新,本次更新采用综述与问题相结合的形式呈现,聚焦于诊断与治疗等方面的内容,对IPFD诊治中的重要问题提出了16条推荐意见,以供我国医务工作者借鉴与参考。.
引用
- [Clinical practice guidelines for the diagnosis and management of invasive pulmonary fungal diseases (2025 Edition)]. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 41362140. doi:10.3760/cma.j.cn112147-20250819-00501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。